Frequent activation of both the RAS/MAPK and PI3K/AKT pathways is documented in almost 50% of HCC patients21; thus, we chose to perform our proof-of-principle therapeutic targeting of the SPINK1 model in the NRasV12+Myr-AKT HTVI-induced HCC model. This evidence concerns the gene AKT1 and hepatocellular carcinoma.